CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 160 enrolled
Drug / intervention
Bepirovirsendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06058390
NCT06058390Phase 1Completed

A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

GlaxoSmithKline·interventional·Posted Sep 28, 2023·Updated Jul 18, 2025

In Brief

A Phase 1 clinical trial evaluating Bepirovirsen for Hepatitis B. Completed, enrolled 160 participants across 2 sites.

Detailed Summary

This is an open-label, randomized study to investigate subcutaneous (SC) bepirovirsen when delivered via SC injection from vial or Prefilled syringe fitted with a Safety syringe device (PFS SSD) in healthy adult participants. The aim of this study is to provide relative bioavailability data to support the transition from the vial presentation of bepirovirsen, to a ready-to-use liquid in a PFS SSD when both are given by a health care professional. The study will also assess self-administration using the PFS SDD, and the safety and tolerability of bepirovirsen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedSep 28, 2023
Enrollment StartOct 4, 2023
Primary CompletionMay 3, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.8 years ago

Interventions

Bepirovirsendrug

Bepirovirsen will be administered.